What is Ideaya Biosciences's earnings per share (EPS)?

Ideaya Biosciences (IDYA) reported diluted earnings per share of $-1.28 for fiscal year 2025. This represents a 61.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Ideaya Biosciences Financials

IDYA

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Ideaya Biosciences (IDYA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IDYA FY2025 2026-05-05

Lumpy revenue recognition can shrink losses quickly, but cash burn still follows research spending in an equity-funded model.

FY2025 revenue jumped to $218.7M from $7.0M, which explains much of the loss improvement after a stretch of minimal reported revenue. But R&D still exceeded revenue at $314.7M and operating cash flow remained negative at -$71.1M, so the better earnings reflect a revenue swing more than a shift to a self-funding operating model.

Free cash flow closely tracked operating cash flow in FY2025, with capex of only $2.4M and FCF of -$73.5M. That points to an asset-light cost structure: cash is being consumed by the research engine and overhead, not by heavy physical reinvestment.

The balance sheet is funded by equity rather than debt, with total liabilities of just $86.4M against assets of $1.11B and no long-term debt reported. Near-term obligations therefore look manageable, but the tradeoff has been dilution, with shares outstanding nearly doubling from 38.5M in FY2021 to 87.8M in FY2025.

Financial Health Signals

Financial Health Score 72/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Ideaya Biosciences's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Safe

24.18

Ideaya Biosciences scores 24.18, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.6B) relative to total liabilities ($86.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/7

Ideaya Biosciences passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.63x

For every $1 of reported earnings, Ideaya Biosciences generates $0.63 in operating cash flow (-$71.1M OCF vs -$113.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$218.7M

YoY+3024.4%

5Y CAGR+62.1%

Ideaya Biosciences generated $218.7M in revenue in fiscal year 2025. This represents an increase of 3024.4% from the prior year.

EBITDA

-$156.6M

YoY+51.8%

Ideaya Biosciences's EBITDA was -$156.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 51.8% from the prior year.

Net Income

-$113.7M

YoY+58.6%

Ideaya Biosciences reported -$113.7M in net income in fiscal year 2025. This represents an increase of 58.6% from the prior year.

EPS (Diluted)

$-1.28

YoY+61.9%

Ideaya Biosciences earned $-1.28 per diluted share (EPS) in fiscal year 2025. This represents an increase of 61.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$73.5M

YoY+70.8%

Ideaya Biosciences generated -$73.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 70.8% from the prior year.

Cash & Debt

$112.8M

YoY+33.7%

5Y CAGR+9.4%

Ideaya Biosciences held $112.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

88M

YoY+0.3%

5Y CAGR+24.3%

Ideaya Biosciences had 88M shares outstanding in fiscal year 2025. This represents an increase of 0.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-72.8%

YoY+4598.2pp

5Y CAGR+108.1pp

Ideaya Biosciences's operating margin was -72.8% in fiscal year 2025, reflecting core business profitability. This is up 4598.2 percentage points from the prior year.

Net Margin

-52.0%

YoY+3869.1pp

5Y CAGR+124.6pp

Ideaya Biosciences's net profit margin was -52.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 3869.1 percentage points from the prior year.

Return on Equity

-11.1%

YoY+14.8pp

5Y CAGR+6.3pp

Ideaya Biosciences's ROE was -11.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 14.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$314.7M

YoY+6.8%

5Y CAGR+51.3%

Ideaya Biosciences invested $314.7M in research and development in fiscal year 2025. This represents an increase of 6.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$2.4M

YoY-38.6%

5Y CAGR+36.9%

Ideaya Biosciences invested $2.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 38.6% from the prior year.

IDYA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$218.7M+3024.4%	$7.0M-70.1%	$23.4M-54.1%	$50.9M+82.3%	$27.9M+43.0%	$19.5M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$314.7M+6.8%	$294.7M+127.5%	$129.5M+44.6%	$89.5M+54.0%	$58.2M+46.5%	$39.7M
SG&A Expenses	$63.3M+61.1%	$39.3M+38.8%	$28.3M+18.5%	$23.9M+19.2%	$20.1M+32.1%	$15.2M
Operating Income	-$159.3M+51.3%	-$327.0M-143.2%	-$134.4M-115.1%	-$62.5M-24.3%	-$50.3M-42.2%	-$35.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$113.7M+58.6%	-$274.5M-143.0%	-$113.0M-92.6%	-$58.7M-17.9%	-$49.8M-44.3%	-$34.5M
EPS (Diluted)	$-1.28+61.9%	$-3.36-71.4%	$-1.96-38.0%	$-1.42-0.7%	$-1.41-0.7%	$-1.40

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$6.6M	N/A	$207.8M	N/A	N/A	N/A	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$95.7M+10.5%	$86.6M+4.3%	$83.0M+11.8%	$74.2M+4.7%	$70.9M	N/A	$57.2M+4.8%	$54.5M
SG&A Expenses	$19.4M	N/A	$16.4M+12.4%	$14.6M+8.0%	$13.5M	N/A	$9.7M-6.3%	$10.4M
Operating Income	-$108.5M	N/A	$108.5M+222.1%	-$88.8M-5.2%	-$84.4M	N/A	-$66.9M-3.0%	-$64.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	N/A	N/A	$0	$0	N/A	$0	$0
Net Income	-$98.5M	N/A	$119.2M+253.9%	-$77.5M-7.4%	-$72.2M	N/A	-$51.8M+1.8%	-$52.8M
EPS (Diluted)	$-1.11	N/A	$1.33+251.1%	$-0.88-7.3%	$-0.82	N/A	$-0.60+11.8%	$-0.68

IDYA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.1B-1.3%	$1.1B+73.1%	$649.3M+67.4%	$388.0M+1.7%	$381.3M+27.9%	$298.3M
Current Assets	$666.7M-3.3%	$689.7M+29.5%	$532.6M+43.8%	$370.5M+47.6%	$251.0M-13.0%	$288.6M
Cash & Equivalents	$112.8M+33.7%	$84.4M-46.3%	$157.0M+128.8%	$68.6M-25.4%	$92.0M+27.8%	$72.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$86.4M+33.0%	$64.9M+130.1%	$28.2M-26.7%	$38.5M-51.8%	$79.8M-20.2%	$100.0M
Current Liabilities	$58.8M+27.7%	$46.1M+70.0%	$27.1M-14.6%	$31.7M-29.8%	$45.2M+16.9%	$38.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.0B-3.4%	$1.1B+70.5%	$621.1M+77.7%	$349.5M+15.9%	$301.5M+52.1%	$198.3M
Retained Earnings	-$736.5M-18.3%	-$622.8M-78.8%	-$348.4M-48.0%	-$235.4M-33.2%	-$176.7M-39.2%	-$127.0M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$1.0B-7.1%	$1.1B-6.4%	$1.2B+13.8%	$1.0B-5.4%	$1.1B-2.1%	$1.1B-9.3%	$1.2B+27.3%	$973.7M
Current Assets	$696.1M+4.4%	$666.7M-16.9%	$802.7M+17.1%	$685.6M-3.1%	$707.9M+2.6%	$689.7M-26.0%	$932.2M+30.7%	$713.2M
Cash & Equivalents	$157.5M+39.6%	$112.8M-62.3%	$298.9M+160.7%	$114.6M-11.8%	$130.0M+54.1%	$84.4M-78.9%	$400.3M+118.7%	$183.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$93.1M+7.7%	$86.4M-7.2%	$93.1M+14.1%	$81.6M+6.7%	$76.5M+17.8%	$64.9M+9.2%	$59.5M+41.5%	$42.0M
Current Liabilities	$64.8M+10.2%	$58.8M-8.8%	$64.5M+16.6%	$55.3M+8.8%	$50.8M+10.4%	$46.1M+13.3%	$40.7M-0.2%	$40.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$937.3M-8.4%	$1.0B-6.3%	$1.1B+13.8%	$959.7M-6.3%	$1.0B-3.3%	$1.1B-10.3%	$1.2B+26.7%	$931.7M
Retained Earnings	-$835.1M-13.4%	-$736.5M-12.7%	-$653.3M+15.4%	-$772.5M-11.1%	-$695.0M-11.6%	-$622.8M-26.5%	-$492.5M-11.8%	-$440.7M

IDYA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$71.1M+71.3%	-$247.6M-114.9%	-$115.2M-32.2%	-$87.2M-56.3%	-$55.8M-200.6%	$55.5M
Capital Expenditures	$2.4M-38.6%	$3.9M+62.9%	$2.4M-31.2%	$3.4M+30.2%	$2.6M+436.3%	$493K
Free Cash Flow	-$73.5M+70.8%	-$251.4M-113.8%	-$117.6M-29.8%	-$90.6M-55.1%	-$58.4M-206.3%	$55.0M
Investing Cash Flow	$70.0M+113.9%	-$502.6M-217.2%	-$158.5M-374.4%	-$33.4M+52.1%	-$69.7M+52.4%	-$146.2M
Financing Cash Flow	$29.8M-95.6%	$677.6M+86.8%	$362.7M+273.3%	$97.2M-33.2%	$145.5M+13.0%	$128.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$75.2M+16.9%	-$90.5M-163.6%	$142.2M+327.6%	-$62.5M-3.5%	-$60.3M+50.4%	-$121.7M-147.1%	-$49.2M-49.7%	-$32.9M
Capital Expenditures	$967K+190.4%	$333K+692.9%	$42K-93.7%	$663K-50.2%	$1.3M+20.7%	$1.1M+141.1%	$457K-53.0%	$973K
Free Cash Flow	-$76.1M+16.2%	-$90.8M-163.9%	$142.2M+325.2%	-$63.1M-2.4%	-$61.7M+49.8%	-$122.8M-147.0%	-$49.7M-46.8%	-$33.9M
Investing Cash Flow	$119.0M+222.0%	-$97.5M-333.5%	$41.8M-9.0%	$45.9M-42.5%	$79.8M+140.5%	-$197.1M-883.8%	-$20.0M-129.2%	$68.6M
Financing Cash Flow	$1.2M-44.6%	$2.1M+607.6%	$301K-75.0%	$1.2M-95.4%	$26.1M+849.6%	$2.8M-99.0%	$286.5M+631.2%	$39.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

IDYA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-72.8%+4598.2pp	-4671.1%-4096.2pp	-574.9%-452.1pp	-122.7%+57.2pp	-179.9%+1.0pp	-180.9%
Net Margin	-52.0%+3869.1pp	-3921.1%-3438.0pp	-483.0%-367.9pp	-115.2%+62.9pp	-178.1%-1.5pp	-176.6%
Return on Equity	-11.1%+14.8pp	-25.9%-7.7pp	-18.2%-1.4pp	-16.8%-0.3pp	-16.5%+0.9pp	-17.4%
Return on Assets	-10.3%+14.2pp	-24.4%-7.0pp	-17.4%-2.3pp	-15.1%-2.1pp	-13.1%-1.5pp	-11.6%
Current Ratio	11.34-3.6	14.97-4.7	19.65+8.0	11.68+6.1	5.56-1.9	7.47
Debt-to-Equity	0.08+0.0	0.06+0.0	0.05-0.1	0.11-0.2	0.26-0.2	0.50
FCF Margin	-33.6%+3558.4pp	-3592.0%-3089.2pp	-502.9%-324.9pp	-177.9%+31.2pp	-209.1%-490.4pp	281.3%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-1654.6%	N/A	52.2%	N/A	N/A	N/A	N/A	N/A
Net Margin	-1502.1%	N/A	57.4%	N/A	N/A	N/A	N/A	N/A
Return on Equity	-10.5%	N/A	10.9%+19.0pp	-8.1%-1.0pp	-7.0%	N/A	-4.4%+1.3pp	-5.7%
Return on Assets	-9.6%	N/A	10.1%+17.5pp	-7.4%-0.9pp	-6.6%	N/A	-4.2%+1.2pp	-5.4%
Current Ratio	10.74-0.6	11.34-1.1	12.44+0.1	12.39-1.5	13.92-1.0	14.97-8.0	22.93+5.4	17.50
Debt-to-Equity	0.10+0.0	0.080.0	0.090.0	0.09+0.0	0.07+0.0	0.06+0.0	0.050.0	0.05
FCF Margin	-1160.6%	N/A	68.4%	N/A	N/A	N/A	N/A	N/A

Similar Companies

Denali Therapeut DNLI

$4.1B

Galapagos Nv GLPG

$1.8B

Amicus Therapeut FOLD

$4.5B

Belite Bio, Inc BLTE

$6.0B

Travere Therapeutics Inc TVTX

$5.3B

Frequently Asked Questions

What is Ideaya Biosciences's annual revenue?

Ideaya Biosciences (IDYA) reported $218.7M in total revenue for fiscal year 2025. This represents a 3024.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Ideaya Biosciences's revenue growing?

Ideaya Biosciences (IDYA) revenue grew by 3024.4% year-over-year, from $7.0M to $218.7M in fiscal year 2025.

Is Ideaya Biosciences profitable?

No, Ideaya Biosciences (IDYA) reported a net income of -$113.7M in fiscal year 2025, with a net profit margin of -52.0%.

What is Ideaya Biosciences's EBITDA?

Ideaya Biosciences (IDYA) had EBITDA of -$156.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Ideaya Biosciences's operating margin?

Ideaya Biosciences (IDYA) had an operating margin of -72.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Ideaya Biosciences's net profit margin?

Ideaya Biosciences (IDYA) had a net profit margin of -52.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Ideaya Biosciences's return on equity (ROE)?

Ideaya Biosciences (IDYA) has a return on equity of -11.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Ideaya Biosciences's free cash flow?

Ideaya Biosciences (IDYA) generated -$73.5M in free cash flow during fiscal year 2025. This represents a 70.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Ideaya Biosciences's operating cash flow?

Ideaya Biosciences (IDYA) generated -$71.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Ideaya Biosciences's total assets?

Ideaya Biosciences (IDYA) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Ideaya Biosciences's capital expenditures?

Ideaya Biosciences (IDYA) invested $2.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Ideaya Biosciences spend on research and development?

Ideaya Biosciences (IDYA) invested $314.7M in research and development during fiscal year 2025.

How many shares does Ideaya Biosciences have outstanding?

Ideaya Biosciences (IDYA) had 88M shares outstanding as of fiscal year 2025.

What is Ideaya Biosciences's current ratio?

Ideaya Biosciences (IDYA) had a current ratio of 11.34 as of fiscal year 2025, which is generally considered healthy.

What is Ideaya Biosciences's debt-to-equity ratio?

Ideaya Biosciences (IDYA) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Ideaya Biosciences's return on assets (ROA)?

Ideaya Biosciences (IDYA) had a return on assets of -10.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Ideaya Biosciences's cash runway?

Based on fiscal year 2025 data, Ideaya Biosciences (IDYA) had $112.8M in cash against an annual operating cash burn of $71.1M. This gives an estimated cash runway of approximately 19 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Ideaya Biosciences's Altman Z-Score?

Ideaya Biosciences (IDYA) has an Altman Z-Score of 24.18, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Ideaya Biosciences's Piotroski F-Score?

Ideaya Biosciences (IDYA) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Ideaya Biosciences's earnings high quality?

Ideaya Biosciences (IDYA) has an earnings quality ratio of 0.63x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Ideaya Biosciences?

Ideaya Biosciences (IDYA) scores 72 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.